Victoria Villaflor, MD, a recent addition to the UCI Health Chao Family Comprehensive Cancer Center faculty, attended the 2025 ASCO Annual Meeting to engage with the latest advances in cancer research and explore how emerging evidence could elevate patient care at UCI Health.

Among the most compelling studies she highlights is the NIVOPOSTOP trial (GORTEC 2018-01), a phase III investigation of adjuvant immunotherapy for patients with high-risk, resected head and neck squamous cell carcinoma. The study evaluated the addition of postoperative nivolumab to standard chemoradiotherapy and demonstrated a 10% improvement in recurrence-free survival—findings that may signal a shift in the standard of care.